SCHEMBL563886

SCHEMBL563886

CCO[PH](=O)Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
PPID Q08752 1/20 0.37
LOXL2 Q9Y4K0 2/20 0.36
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
MAOB P27338 1/20 0.34
F2 P00734 1/20 0.34
PLG P00747 1/20 0.34
ELANE P08246 1/20 0.34
CTSG P08311 1/20 0.34
CMA1 P23946 1/20 0.34
CTRC Q99895 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP2A6 P11509 1/20 0.33
HTR2A P28223 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8812669 0.85 MAOB (0.53) MAOBSMN1; SMN2
SCHEMBL11488455 0.84 LMNA (0.39) TP53LOXL2ALDH1A1TSHRSMN1; SMN2
SCHEMBL10051635 0.83 TAAR1 (0.40) TP53IDO1ALDH1A1SMN1; SMN2CYP2A6
SCHEMBL27579738 0.82 LOXL2 (0.43) PPIDLOXL2ALDH1A1TSHRMAOB
SCHEMBL5482816 0.82 IDO1 (0.41) TP53IDO1ALDH1A1SMN1; SMN2CYP2A6
SCHEMBL11488537 0.81 ALDH1A1 (0.43) ALDH1A1TSHRSMN1; SMN2
SCHEMBL969878 0.81 TSHR (0.46) LOXL2IDO1ALDH1A1TSHRMAOB
SCHEMBL8814962 0.80 ESR1 (0.40) TP53IDO1ALDH1A1TAAR1
SCHEMBL8290989 0.80 TAAR1 (0.40) TP53LOXL2ALDH1A1MAOBCMA1
SCHEMBL27557933 0.80 TAAR1 (0.38) IDO1SMN1; SMN2HTR2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0185132-B1 NOVEL ETHYL BENZYLPHOSPHINATE DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND THEIR USE AS CALCIUM ANTAGONIST KANEBO, LTD. (JP) 1988-08-10 EP claimed
US-4607031-A REACTING A PHOSPHONOCHLORIDATE HYDROCHLORIDE WITH ALKALI METAL SALT OF LACTAM KANEBO LTD. (JP) 1986-08-19 US claimed
EP-0185132-A1 Novel ethyl benzylphosphinate derivatives, process for production thereof, and their use as calcium antagonist KANEBO, LTD. (JP) 1986-06-25 EP claimed
EP-2957514-B1 MULTI-LAYER BOTTLE AND METHOD FOR PRODUCING SAME MITSUBISHI GAS CHEMICAL CO (JP) 2021-08-04 EP disclosed
US-10144548-B2 Multi-layer bottle and method for producing same MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2018-12-04 US disclosed
US-20160001914-A1 MULTI-LAYER BOTTLE AND METHOD FOR PRODUCING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2016-01-07 US disclosed
EP-2957514-A1 MULTI-LAYER BOTTLE AND METHOD FOR PRODUCING SAME Mitsubishi Gas Chemical Company, Inc. (JP) 2015-12-23 EP disclosed
EP-1673377-B1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES AVENTIS PHARMA INC (US) 2013-12-25 EP disclosed
EP-2038290-B1 MODULATORS OF TOLL-LIKE RECEPTOR 7 GILEAD SCIENCES INC (US) 2013-09-04 EP disclosed
US-8338593-B2 Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-20120034480-A1 Catalyst for producing polyesters and polyester resin composition SAKAMOTO JUN (JP) 2012-02-09 US disclosed
US-5407922-A GABA antagonists CIBA-GEIGY CORPORATION (US) 1995-04-18 US disclosed
US-5229379-A Gamma-aminobutyric acid antagonists CIBA-GEIGY CORPORATION (US) 1993-07-20 US disclosed
EP-0185132-B1 NOVEL ETHYL BENZYLPHOSPHINATE DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND THEIR USE AS CALCIUM ANTAGONIST KANEBO, LTD. (JP) 1988-08-10 EP disclosed
US-4607031-A REACTING A PHOSPHONOCHLORIDATE HYDROCHLORIDE WITH ALKALI METAL SALT OF LACTAM KANEBO LTD. (JP) 1986-08-19 US disclosed
US-4607031-A REACTING A PHOSPHONOCHLORIDATE HYDROCHLORIDE WITH ALKALI METAL SALT OF LACTAM KANEBO LTD. (JP) 1986-08-19 US disclosed
US-4607031-A REACTING A PHOSPHONOCHLORIDATE HYDROCHLORIDE WITH ALKALI METAL SALT OF LACTAM KANEBO LTD. (JP) 1986-08-19 US disclosed
EP-0185132-A1 Novel ethyl benzylphosphinate derivatives, process for production thereof, and their use as calcium antagonist KANEBO, LTD. (JP) 1986-06-25 EP disclosed
EP-0185132-A1 Novel ethyl benzylphosphinate derivatives, process for production thereof, and their use as calcium antagonist KANEBO, LTD. (JP) 1986-06-25 EP disclosed
EP-0185132-A1 Novel ethyl benzylphosphinate derivatives, process for production thereof, and their use as calcium antagonist KANEBO, LTD. (JP) 1986-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120034480-A1 Catalyst for producing polyesters and polyester resin composition PUF60, RPS24, SRP54 TP53 1839/4885PPID 3477/4885LOXL2 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.